6533b82afe1ef96bd128c189
RESEARCH PRODUCT
A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer.
Natascha StergiouNicole TeuschHorst KunzBjörn PalitzschEdgar SchmittSebastian HartmannNikola GaidzikBastian GerlitzkiPeer FlemmingSonja Stahnsubject
medicine.drug_classmedicine.medical_treatmentTumor M2-PKBreast NeoplasmsBiology010402 general chemistryMonoclonal antibody01 natural sciencesCancer VaccinesCatalysisCancer immunotherapyAntigenPancreatic tumorPancreatic cancermedicineHumansBreastMUC1010405 organic chemistryMucinGlycopeptidesAntibodies MonoclonalGeneral Chemistrymedicine.diseaseMolecular biology0104 chemical sciencesPancreatic NeoplasmsFemaledescription
In studies within the realm of cancer immunotherapy, the synthesis of exactly specified tumor-associated glycopeptide antigens is shown to be a key strategy for obtaining a highly selective biological reagent, that is, a monoclonal antibody that completely differentiates between tumor and normal epithelial cells and specifically marks the tumor cells in pancreas tumors. Mucin MUC1, which is overexpressed in many prevalent cancers, was identified as a promising target for this strategy. Tumor-associated MUC1 differs significantly from that expressed by normal cells, in particular by altered glycosylation. Structurally defined tumor-associated MUC1 cannot be isolated from tumor cells. We synthesized MUC1-glycopeptide vaccines and analyzed their structure-activity relationships in immunizations; a monoclonal antibody that specifically distinguishes between human normal and tumor epithelial cells was thus generated.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-11-02 | Angewandte Chemie (International ed. in English) |